Replies to post #660 on Acasti Pharma, Inc (ACST)

[Amatuer17]

“ Also, VC has done an outcome trial and CP has not. But the thinking is that FDA may start to look at N-3 drugs as a class, especially if the upcoming STRENGTH trial data from AstraZeneca is good, as I believe it will be.”

This is an interesting observation.
ACST is doing 2nd follow up trial and it’s topline results will come in 4-6 weeks after 1st trial.

Question - if results from both the trials are very good - will it allow them to file NDA or as none of the trials are announced as pivotal, will they need to conduct another larger trial? Or they will need to carry an outcome trial like VC and it will be long duration.

[CoolG73]

Thx JB, very informative. This confirms what I was told by a longtime shareholder that that delay was decided following Haywood recommendation. It also confirms my suspicion that the real leak on the TG numbers happened on the week of Dec 16, confirming the trial success

[CoolG73]

JB, I guess we need to add another week to the timeline mentioned in the update you posted, because we need to take into account the delay ACST mentioned in their PR